Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 1 Study of HCB303 in Participants With Advanced Malignancies

A Phase 1, Open-label, Multi-regional, Multicenter, Dose escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of HCB303 in Participants with Advanced Malignancies

Participants needed: 150
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: FBD Biologics LimitedUpdated: Oct 5, 2026
Eligibility criteria

The participant is able to understand and willing to provide signed informed con... [+4]

Other malignancies requiring treatment within 2 years before the first dose of H... [+1]

Read more
Status: Recruiting

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Participants needed: 50
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: FBD Biologics LimitedUpdated: Apr 13, 2026Locations: 7
Eligibility criteria

Able to understand and be willing to sign the ICF. [+6]

With known history of hypersensitivity to any components of HCB301. [+15]

Read more
Status: Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Participants needed: 80
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: FBD Biologics LimitedUpdated: Feb 4, 2026Locations: 8
Eligibility criteria

Able to understand and willing to sign the ICF. [+7]

With known history of hypersensitivity to any components of HCB101. [+16]

Read more